Pulse Biosciences (NASDAQ:PLSE) COO Liane Rae Teplitsky Buys 1,036 Shares

by · The Markets Daily

Pulse Biosciences, Inc (NASDAQ:PLSE – Get Free Report) COO Liane Rae Teplitsky acquired 1,036 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were bought at an average price of $48.23 per share, for a total transaction of $49,966.28. Following the acquisition, the chief operating officer owned 1,036 shares in the company, valued at approximately $49,966.28. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Liane Rae Teplitsky also recently made the following trade(s):

  • On Friday, August 28th, Liane Rae Teplitsky acquired 1,034 shares of Pulse Biosciences stock. The shares were purchased at an average cost of $48.35 per share, with a total value of $49,993.90.

Pulse Biosciences Trading Down 2.0%

PLSE stock traded down $0.99 during mid-day trading on Friday, reaching $47.57. 262,703 shares of the stock traded hands, compared to its average volume of 406,808. Pulse Biosciences, Inc has a 52-week low of $12.56 and a 52-week high of $50.90. The stock’s fifty day moving average is $35.38 and its 200-day moving average is $27.00. The company has a market cap of $3.29 billion, a P/E ratio of -40.31 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The firm had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Equities research analysts expect that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PLSE. Canaccord Genuity Group raised their price objective on Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Oppenheimer reiterated an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Needham & Company LLC assumed coverage on shares of Pulse Biosciences in a research report on Monday, August 17th. They issued a “buy” rating and a $58.00 price target for the company. Finally, Mizuho set a $45.00 price target on shares of Pulse Biosciences in a report on Monday, August 10th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Pulse Biosciences has an average rating of “Moderate Buy” and an average price target of $45.25.

Get Our Latest Report on Pulse Biosciences

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its stake in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after purchasing an additional 680 shares in the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Pulse Biosciences in the 2nd quarter valued at approximately $28,000. Tower Research Capital LLC TRC increased its holdings in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after buying an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after buying an additional 619 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in Pulse Biosciences during the second quarter valued at approximately $158,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

(Get Free Report)

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

Read More